FDA Approves AstraZeneca's Breast Cancer Pill Etcamah (Camizestrant)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's camizestrant, branded as Etcamah, for the treatment of a genetically driven form of metastatic breast cancer. This approval follows an earlier advisory panel vote against the medicine.